Form 8-K - Current report:
SEC Accession No. 0001493152-21-021927
Filing Date
2021-09-03
Accepted
2021-09-03 07:00:46
Documents
15
Period of Report
2021-08-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 67751
2 ex10-1.htm EX-10.1 40048
3 ex99-1.htm EX-99.1 20691
4 ex99-1_001.jpg GRAPHIC 3540
  Complete submission text file 0001493152-21-021927.txt   315010

Data Files

Seq Description Document Type Size
5 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT otlc-20210831.xsd EX-101.SCH 3027
6 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT otlc-20210831_lab.xml EX-101.LAB 34239
7 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT otlc-20210831_pre.xml EX-101.PRE 22360
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3291
Mailing Address 29397 AGOURA RD. #107 AGUORA HILLS CA 91301
Business Address 29397 AGOURA RD. #107 AGUORA HILLS CA 91301 650-635-7000
Oncotelic Therapeutics, Inc. (Filer) CIK: 0000908259 (see all company filings)

IRS No.: 133679168 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-21990 | Film No.: 211235124
SIC: 2834 Pharmaceutical Preparations